FBXW7, a novel E3 ubiquitin ligase, was identified as the major regulator of CRY2-mediated chemosensitivity, which promotes ubiquitin-mediated degradation of CRY2 leading to downregulation of CRY2 and increased CRC cell response to oxaliplatin [46]. The gene discussed is CRY2; the disease is colorectal carcinoma.